24.04
+0.33
(1.39%)
After Hours: 24.07
+0.03
(0.12%)
Jul 31, 7:59PM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 23.90 - 24.49 |
| 52 week | 16.63 - 24.49 |
| Open | 23.91 |
| Vol / Avg. | 0.00/35.25M |
| Mkt cap | 180.01B |
| P/E | 22.59 |
| Div/yield | 0.22/3.66 |
| EPS | 1.06 |
| Shares | 7.49B |
| Beta | 0.69 |
| Inst. own | 72% |
Events
Jul 31, 2012
Q2 2012 Pfizer Earnings Conference Call
Jul 12, 2012
Verastem Inc Research and Development Day and discussion of acquisition of Clinical-Stage FAK Inhibitor from Pfizer -
Jun 3, 2012
Pfizer at American Society of Clinical Oncology Annual Meeting -
May 17, 2012
Pfizer at Bank of America Merrill Lynch Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q2 (Apr '12) | 2011 | |
| Net profit margin | 11.70% | 12.96% |
| Operating margin | 16.57% | 18.93% |
| EBITD margin | - | 34.13% |
| Return on average assets | 3.87% | 4.56% |
| Return on average equity | 8.70% | 10.24% |
| Employees | 103,700 | - |
| Carbon Disclosure Rating | - | 81/100 |
Address
235 East 42nd Street
NEW YORK, NY 10017-5755
United States - Map
+1-212-7332323 (Phone)
+1-302-6555049 (Fax)
NEW YORK, NY 10017-5755
United States - Map
+1-212-7332323 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
About Company - Wikipedia
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health and Consumer Healthcare, and Nutrition. The Company�s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Its Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. On August 1, 2011, it completed the sale of its Capsugel business. In October 2011, it acquired Icagen, Inc. In December 2011, it acquired the consumer healthcare business of Ferrosan Holding A/S. In December 2011, it acquired Excaliard Pharmaceuticals, Inc.
Officers and directors
| Ian C. Read | Chairman of the Board, President, Chief Executive Officer | |
| Frank A. D'Amelio | Chief Financial Officer, Executive Vice President - Business Operations | |
| Mikael Dolsten M.D., Ph.D. | President - Worldwide Research and Development | |
| Cavan M. Redmond | Group President - Animal Health, Consumer Healthcare and Corporate Strategy | |
| Douglas M. Lankler | Executive Vice President, Chief Compliance and Risk Officer | |
| Amy W. Schulman | Executive Vice President, General Counsel, President and General Manager - Nutrition | |
| Charles H. Hill III | Executive Vice President - Worldwide Human Resources | |
| Freda C. Lewis-Hall M.D. | Executive Vice President, Chief Medical Officer | |
| Laurie Olson | Executive Vice President - Strategy, Portfolio Management and Global Commercial Operations | |
| Kristin C. Peck | Executive Vice President - Worldwide Business Development and Innovation |